Filing Flows › NewAmsterdam Pharma Co N.V. (NAMS) › Recalls, complaints & regulation

NewAmsterdam Pharma Co N.V. (NAMS): clinical trials

NewAmsterdam Pharma Co N.V. (NAMS) beyond its filings: 6 active clinical trials.

NewAmsterdam Pharma Co N.V.'s latest quarter

NewAmsterdam Pharma Co N.V., Q3 2026: revenue $19.2M (55× year over year), operating margin -230.6%, net loss $17.4M, operating cash flow −$39.8M. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does NewAmsterdam Pharma Co N.V. have?

6 active studies on ClinicalTrials.gov, 3 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.